José L Arias
José L Arias
Introduction: Drug therapy is frequently limited by the widespread biodistribution of the active agents and the little specificity for non-healthy cells. Therefore, inadequate drug concentrations result into the site of a...
Novel small molecule epithelial sodium channel inhibitors as potential therapeutics in cystic fibrosis - a patent evaluation [0.03%]
用于囊性纤维化疾病的新型小分子上皮钠通道抑制剂潜在治疗药物-专利评估
Matthias Schoenberger,Mike Althaus
Matthias Schoenberger
Novel molecular platforms for epithelial sodium channel (ENaC) modulators are claimed in the following six patents: WO2012035158(A1); WO2009074575(A2); WO2011028740(A1); WO2009150137(A2); WO2011079087(A1); WO2008135557(A1). These ENaC inhib...
Fei Liu,Yong-Qing Wang,Ling Meng et al.
Fei Liu et al.
Introduction: FK506-binding protein 12 (FKBP12) is an endogenous protein with peptidyl-prolyl isomerase (PPIase) activity. Natural compounds FK506, rapamycin and ascomycin, are FKBP12 ligands used for treating organ trans...
Evaluation of WO2012177707 and WO2012097269: Vertex's phosphate prodrugs of gyrase and topoisomerase antibacterial agents [0.03%]
WO2012177707和WO2012097269的评估：Vertex的DNA gyrase和拓扑异构酶抗菌剂焦磷酸前药
John Finn
John Finn
The two patent applications describe two novel compounds in the benzimidazole class of GyrB/ParE antibacterial agents and multiple phosphate prodrugs derived from these compounds. The new benzimidazole compounds have excellent antibacterial...
Vathan Kumar,Young-Sik Jung,Po-Huang Liang
Vathan Kumar
Introduction: A novel coronavirus (CoV), unlike previous typical human coronaviruses (HCoVs), was identified as causative agent for severe acute respiratory syndrome (SARS). SARS first surfaced as a pandemic in late 2002 ...
Novel γ-secretase modulators for the treatment of Alzheimer's disease: a review focusing on patents from 2010 to 2012 [0.03%]
阿尔茨海默病治疗的新γ-分泌酶调节剂：2010—2012年专利的综述
Martin Pettersson,Antonia F Stepan,Gregory W Kauffman et al.
Martin Pettersson et al.
Introduction: γ-Secretase is the enzyme responsible for the final step of amyloid precursor protein proteolysis to generate Aβ peptides including Aβ42 which is believed to be a toxic species involved in Alzheimer's dis...
Crystalline forms of 2,2,2-trifluoro-N-[(1R,2S)-1-{[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy}-1-(3-methoxyphenyl)-2-propanyl]acetamide (AZD-5423) [0.03%]
2,2,2-三氟-N-[(1R,2S)-1-{[1-(4-氟苯基)-1H-吲达唑-5-基]氧}-1-(3-甲氧基苯基)-2-丙基]乙酰胺(AZD-5423)的多晶型研究
Peter Norman
Peter Norman
A crystalline form (form B) of the novel glucocorticoid receptor agonist 2,2,2-trifluoro-N-[(1R,2S)-1-{[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy}-1-(3-methoxyphenyl)-2-propanyl]acetamide (AZD-5423) and its use alone or in combination for the ...
Simon Cohen,Paul England
Simon Cohen
1,3-Oxazines as BACE1 and/or BACE2 inhibitors: a patent evaluation (WO2012156284) [0.03%]
1,3-恶嗪类作为BACE1和/或BACE2抑制剂：一项专利评估（WO2012156284）
Eric J Gilbert
Eric J Gilbert
This patent review covers the contents of Hoffman-La Roche and Siena Biotech's patent application WO2012156284 titled '1,3-Oxazines as BACE1 and/or BACE2 Inhibitors.' Beta-site amyloid precursor protein-converting enzyme (BACE1) and BACE2 a...
Strategic considerations under the Biologics Price Competition and Innovation Act [0.03%]
生物制品价格竞争和创新法案的战略考量
John L Marquardt,Stephen R Auten
John L Marquardt
The Biologics Price Competition and Innovation Act provides a pathway for regulatory approval of generic drugs and the associated patent challenge. This article reviews strategic considerations during the patent litigation and injunction ph...